RESUMO
Two adolescent females and a girl, all with clinically diagnosed vitiligo, were treated with 0.2% 8-methoxypsoralen cream followed by exposure to solar ultraviolet light. One year later, they developed hypopigmented and achromic spots on the areas affected by the vitiligo. Biopsy of skin tissue taken from one of these cases showed a marked reduction in melanin. Clinical and histological findings point to a diagnosis of leukoderma punctata.
Assuntos
Metoxaleno/efeitos adversos , Terapia PUVA/efeitos adversos , Fármacos Fotossensibilizantes/efeitos adversos , Transtornos da Pigmentação/etiologia , Adolescente , Criança , Feminino , Humanos , Metoxaleno/uso terapêutico , Fármacos Fotossensibilizantes/uso terapêutico , Transtornos da Pigmentação/patologia , Vitiligo/tratamento farmacológicoRESUMO
Duas adolescentes e uma menina com vitiligo clinicamente diagnosticado foram tratadas com 8-metoxipsoraleno a 0,2 por cento em creme Lanette com subsequente exposição solar. Um ano após, apresentaram máculas acrômicas na área do vitiligo. A biópsia de pele em um dos casos revelou melanócitos com escassa pigmentação melânica. Os achados clínicos e histológicos sugerem o diagnóstico de leucodermia punctata.
Two adolescent females and a girl, all with clinically diagnosed vitiligo, were treated with 0.2 percent 8-methoxypsoralen cream followed by exposure to solar ultraviolet light. One year later, they developed hypopigmented and achromic spots on the areas affected by the vitiligo. Biopsy of skin tissue taken from one of these cases showed a marked reduction in melanin. Clinical and histological findings point to a diagnosis of leukoderma punctata.
Assuntos
Adolescente , Criança , Feminino , Humanos , Metoxaleno/efeitos adversos , Terapia PUVA/efeitos adversos , Fármacos Fotossensibilizantes/efeitos adversos , Transtornos da Pigmentação/etiologia , Metoxaleno/uso terapêutico , Fármacos Fotossensibilizantes/uso terapêutico , Transtornos da Pigmentação/patologia , Vitiligo/tratamento farmacológicoRESUMO
A child was treated from age 18 months to 8 years with oral methoxsalen and ultraviolet A radiation (PUVA) for refractory psoriasis. Two basal cell cancers developed before age 21 years, suggesting that exposure to PUVA in childhood increases the risk of basal cell cancer.
Assuntos
Carcinoma Basocelular/etiologia , Metoxaleno/administração & dosagem , Neoplasias Induzidas por Radiação/etiologia , Terapia PUVA/efeitos adversos , Neoplasias Cutâneas/etiologia , Administração Oral , Adolescente , Carcinoma Basocelular/patologia , Seguimentos , Humanos , Masculino , Metoxaleno/efeitos adversos , Neoplasias Induzidas por Radiação/patologia , Psoríase/complicações , Psoríase/tratamento farmacológico , Fatores de Risco , Neoplasias Cutâneas/patologia , Fatores de TempoRESUMO
Extensive psoriasis in 1,308 patients has been treated two or three times a week with oral 8-methoxypsoralen followed by high intensity, long-wave ultraviolet light (PUVA). Excluding 169 patients still under early treatment, psoriasis cleared in 88% and failed to clear in 3%. One percent dropped out due to complications of treatment, and 8% for other reasons. The twice-a-week schedule was superior for patients with lighter skin types. Once a remission was induced, there was no difference in its maintenance when patients were treated once a week, once every other week, or once every third week. Each of these schedules was superior to no maintenance treatment. Immediate side effect of the 45,000 treatments administered in the first 18 months of this study were uncommon, temporary, and generally mild. No clinically significant changes in laboratory screening or eye examinations attributable to PUVA have been uncovered.